Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese

Inclusion Criteria: * 3-5 months old group * Healthy infants aged 3-5months old as established by medical history and clinical examination * Subjects who was never administered meningococcal vaccine. * The subjects' guardians are able to understand and sign the informed consent * Subjects who can and will comply with the requirements of the protocol * Subjects with temperature ≤37.0°C on axillary setting 6-23 months old group * Healthy infants aged 6-23 months old as established by medical history and clinical examination * Subjects who was never administered meningococcal conjugate vaccine, or administered meningococcal polysaccharide vaccine over 3 months. * The subjects' guardians are able to understand and sign the informed consent * Subjects who can and will comply with the requirements of the protocol * Subjects with temperature ≤37.0°C on axillary setting 2-5 years old group * Healthy infants aged 2-5 years as established by medical history and clinical examination * Subjects who was never administered meningococcal conjugate vaccine, or administered meningococcal polysaccharide vaccine over 12 months. * The subjects' guardians are able to understand and sign the informed consent * Subjects who can and will comply with the requirements of the protocol * Subjects with temperature ≤37.0°C on axillary setting Exclusion Criteria: * Subjects who has a medical history of invasive meningococcal disease and meningococcal meningitis. * Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine * Severe malnutrition or dysgenopathy * Family history of seizures or progressive neurological disease * Family history of congenital or hereditary immunodeficiency * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with injections or blood draws * Any acute infections in last 3 days * Any prior administration of immunodepressant or corticosteroids in last 14 days * Any prior administration of attenuated live vaccine in last 14 days * Any prior administration of subunit or inactivated vaccines in last 7 days * Had fever before vaccination, Subjects with temperature \>37.0°C on axillary setting * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives Exclusion Criteria for the second and third dose: If Subjects who have one condition as followed, prohibiting to continue the vaccination, and they will be continue observed in the opinion of the investigator. All participants with adverse events as followed, must be settled in follow-up to the end of events. * Any serious adverse events caused by vaccination. * Any confirmed or suspected autoimmune diseases or immune deficiency disorders, including human immunodeficiency virus (HIV) infection * Have acute or new chronic disease during vaccination * Other reactions that in the opinion of the investigator ( include: severely serious symptom of pain, swelling, Limitation of motion, continuous high fever, headache and other Systemic or local reactions )